针对免疫检查点的乳腺癌治疗研究进展

发布时间：2018-04-11 13:26

本文选题：乳腺癌 + 免疫检查点　；参考：《中国肿瘤生物治疗杂志》2017年12期

【摘要】：通过免疫检查点分子和配体结合而激活的免疫检查点通路是活化免疫细胞的抑制性第二信号,维持机体自身免疫耐受,抑制免疫过度激活从而保护自身组织。其中主要包括CTLA-4/CD80、CD86,PD-1/PD-L1,A2a R/细胞外腺苷和Tim-3/半乳凝素-9等。乳腺癌细胞通过高表达免疫检查点分子配体介导免疫逃逸,通过PI3K通路、JAK/STAT通路和NF-κB通路参与免疫作用机制。目前,针对免疫检查点的乳腺癌治疗策略包括直接阻断T细胞表面的免疫检查点分子,如单克隆抗体单一治疗、单克隆抗体间联合治疗、单克隆抗体联合化疗药物治疗、单克隆抗体联合物理疗法、基因靶向治疗等,以及间接阻断肿瘤细胞及其微环境的免疫检查点分子配体,其研究热点主要集中在PD-L1上,具体方法主要为单克隆抗体以及基因靶向治疗。
[Abstract]:The immune checkpoint molecule and the ligand binding and activation of the immune checkpoint pathway is inhibited second signal activation of immune cells, maintain immune tolerance, immune suppression and protection of their excessive activation of organization. Including CTLA-4/CD80, CD86, PD-1/PD-L1, A2a, R/ and Tim-3/ extracellular adenosine galectin -9 breast cancer. The high expression of cell immune checkpoint ligand mediated immune escape through the PI3K pathway, JAK/STAT pathway and NF- B pathway involved in immune mechanism. At present, for the treatment of breast cancer. Immune checkpoint including directly blocking the immune checkpoint molecule on the surface of T cell, such as monoclonal antibody monotherapy, combination therapy of monoclonal antibodies among the monoclonal antibody combined with chemotherapy drugs. The monoclonal antibody combined with physical therapy, gene therapy, and indirect blocking tumor cells and micro The molecular ligands of environmental immunologic checkpoints are mainly focused on PD-L1, and the specific methods are mainly monoclonal antibodies and gene targeting therapy.

【作者单位】：空军军医大学基础医学院;空军军医大学航空航天医学系教育部航空航天医学重点实验室;
【分类号】：R737.9

【相似文献】